[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Das et al., 2017 - Google Patents

Tim‐3 and its role in regulating anti‐tumor immunity

Das et al., 2017

View PDF
Document ID
9474138956640578899
Author
Das M
Zhu C
Kuchroo V
Publication year
Publication venue
Immunological reviews

External Links

Snippet

Immunotherapy is being increasingly recognized as a key therapeutic modality to treat cancer and represents one of the most exciting treatments for the disease. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Das et al. Tim‐3 and its role in regulating anti‐tumor immunity
Lin et al. Heterogeneity of HLA-G expression in cancers: facing the challenges
Yamamoto et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Tian et al. The role of GITR/GITRL interaction in autoimmune diseases
Simhadri et al. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function
Rodriguez‐Manzanet et al. The costimulatory role of TIM molecules
Wang et al. IgE actions on CD 4+ T cells, mast cells, and macrophages participate in the pathogenesis of experimental abdominal aortic aneurysms
Bacher et al. Interferon-α suppresses cAMP to disarm human regulatory T cells
Lin et al. Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy
Rouas-Freiss et al. The dual role of HLA‐G in cancer
Wu et al. TLR ligand induced IL-6 counter-regulates the anti-viral CD8+ T cell response during an acute retrovirus infection
Campoli et al. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands
Sharma et al. Regulatory T cells in acute and chronic kidney diseases
Attridge et al. IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase–dependent upregulation of CD86 on B cells
Abdallah et al. Leukocyte immunoglobulin-like receptors in regulating the immune response in infectious diseases: A window of opportunity to pathogen persistence and a sound target in therapeutics
Zhao et al. Growth Arrest‐Specific 6 Enhances the Suppressive Function of CD4+ CD25+ Regulatory T Cells Mainly through Axl Receptor
Ito et al. mTOR complex signaling through the SEMA4A–Plexin B2 axis is required for optimal activation and differentiation of CD8+ T cells
Zilberman et al. HLA‐G 1 and HLA‐G 5 active dimers are present in malignant cells and effusions: The influence of the tumor microenvironment
Lee et al. Enrichment of human CCR6+ regulatory T cells with superior suppressive activity in oral cancer
Zhu et al. Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer
Nardi et al. Soluble monomers, dimers and HLA‐G‐expressing extracellular vesicles: the three dimensions of structural complexity to use HLA‐G as a clinical biomarker
Wang et al. CD226 attenuates Treg suppressive capacity via CTLA-4 and TIGIT during EAE
Morandi et al. A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis
Karakhanova et al. ERK/p38 MAP‐kinases and PI3K are involved in the differential regulation of B7‐H1 expression in DC subsets
Redondo-García et al. Human leukocyte immunoglobulin-like receptors in health and disease